Lemairamin
Based on 1 Customer Validation
Lemairamin (Wgx-50) is a hydroxylamine compound. Lemairamin can be isolated from the pericarps of the Zanthoxylum plants. Lemairamin activates α7nAChR, stimulates the expression of IL-10 and POMC. Lemairamin shows a decrease in Akt. Lemairamin attenuates DSS-induced intestinal inflammation. Lemairamin alleviates pain hypersensitivity.
For research use only. We do not sell to patients.
- Purity : 99.90%
- CAS No.: 29946-61-0
- Formula: C19H21NO3
- Molecular Weight:311.37
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
|
IL-10 |
IL-6 |
IL-1β |
In Vitro
In Vivo
Lemairamin (1-300 mg/kg; s.c.) dose-dependently inhibits formalin-induced tonic pain in male Swiss mice with an Emax of 66.7% inhibition and an ED50 of 11.1 mg/kg, via activation of α7nAChRs[2].
Lemairamin (1-300 mg/kg; s.c.; single administration) dose-dependently inhibits formalin-induced tonic pain in adult Wistar rats with an Emax of 45.9% inhibition and an ED50 of 21.9 mg/kg[2].
Lemairamin (10-300 μg; i.t.; single administration) dose-dependently reduces mechanical allodynia in L5/L6 spinal nerve ligated Wistar rats with an Emax of 60.4% MPE and an ED50 of 83.9 μg, via α7nAChR activation and subsequent stimulation of spinal IL-10 and β-endorphin expression[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:wild-type (WT); Tg(lyz:EGFP) (transgenic for neutrophil labeling; 3-day-post-fertilization; DSS-induced intestinal inflammation)[1]
-
Dosage:10 μL/L
-
Administration:6, 12, or 18 hours
-
Result:Suppressed recruitment of neutrophils to the intestinal injury site, with the most significant reduction observed at 12 hours.
Significantly reduced the relative mRNA expression levels of pro-inflammatory cytokines il-1β, il-6, cxcl8a, and tnf-α, with the most significant reduction at 12 hours.
Preserved intestinal morphology, including intact, well-arranged intestinal epithelial cell structure, normal glandular structure, reduced intestinal vacuoles, alleviated DSS-induced increases in crypt depth, and restored the villus length to crypt depth ratio.
Significantly decreased the relative protein expression of p-Akt/Akt compared to the DSS-only group.
Significantly downregulated the relative mRNA expression levels of akt1, akt2, and akt3, which were upregulated by DSS treatment.
Chemical Information
-
CAS No. 29946-61-0
-
Appearance Solid
-
Molecular Weight 311.37
-
Formula C19H21NO3
-
Color White to off-white
-
SMILES
O=C(/C=C/C1=CC=CC=C1)NCCC2=CC(OC)=C(C=C2)OC
-
Synonyms
Wgx-50
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (321.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.03 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhang L, et al. Lemairamin (Wgx-50) Attenuates DSS-Induced Intestinal Inflammation in Zebrafish. Int J Mol Sci. 2024;25(17):9510. Published 2024 Sep 1. [Content Brief]
[2]. Wang ZY, et al. Lemairamin, isolated from the Zanthoxylum plants, alleviates pain hypersensitivity via spinal α7 nicotinic acetylcholine receptors. Biochem Biophys Res Commun. 2020;525(4):1087-1094. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2116 mL | 16.0581 mL | 32.1161 mL | 80.2903 mL |
| 5 mM | 0.6423 mL | 3.2116 mL | 6.4232 mL | 16.0581 mL | |
| 10 mM | 0.3212 mL | 1.6058 mL | 3.2116 mL | 8.0290 mL | |
| 15 mM | 0.2141 mL | 1.0705 mL | 2.1411 mL | 5.3527 mL | |
| 20 mM | 0.1606 mL | 0.8029 mL | 1.6058 mL | 4.0145 mL | |
| 25 mM | 0.1285 mL | 0.6423 mL | 1.2846 mL | 3.2116 mL | |
| 30 mM | 0.1071 mL | 0.5353 mL | 1.0705 mL | 2.6763 mL | |
| 40 mM | 0.0803 mL | 0.4015 mL | 0.8029 mL | 2.0073 mL | |
| 50 mM | 0.0642 mL | 0.3212 mL | 0.6423 mL | 1.6058 mL | |
| 60 mM | 0.0535 mL | 0.2676 mL | 0.5353 mL | 1.3382 mL | |
| 80 mM | 0.0401 mL | 0.2007 mL | 0.4015 mL | 1.0036 mL | |
| 100 mM | 0.0321 mL | 0.1606 mL | 0.3212 mL | 0.8029 mL |
Lemairamin Related Classifications
HY-N18367 Related Classifications
Powered by Bioz